About: Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: A$0.03 (-8.11%)
IVX ASX Invion Ltd
Invion Ltd share price
IVX price activity
Last Price
$0.030
Change (24hr)
-0.00 AUD (8.11%)
Volume
17.16K
Volume (4w avg)
-
Open
$0.04
Day Range
$0.03 - $0.04
Previous Close
$0.04
Last Trade
04 Nov, 3:35 am GMT+0
Delayed
04 Nov, 3:35 am GMT+0
IVX price performance
Delayed
04 Nov, 3:35 am GMT+0
IVX details
IVX Market Signals